Iterum Therapeutics Plc Stock Buy Hold or Sell Recommendation
| ITRM Stock | USD 1.81 0.04 2.26% |
Given the investment horizon of 90 days and your highly speculative risk level, our recommendation regarding Iterum Therapeutics PLC is 'Strong Sell'. The recommendation algorithm takes into account all of Iterum Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Iterum Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Iterum and provide practical buy, sell, or hold advice based on investors' constraints. Iterum Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Iterum |
Execute Iterum Therapeutics Buy or Sell Advice
The Iterum recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Iterum Therapeutics PLC. Macroaxis does not own or have any residual interests in Iterum Therapeutics PLC or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Iterum Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | OK | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Very regressive towards the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Iterum Therapeutics Trading Alerts and Improvement Suggestions
| Iterum Therapeutics is way too risky over 90 days horizon | |
| Iterum Therapeutics may become a speculative penny stock | |
| Iterum Therapeutics appears to be risky and price may revert if volatility continues | |
| Iterum Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (38.37 M) with profit before overhead, payroll, taxes, and interest of 37 K. | |
| Iterum Therapeutics PLC currently holds about 68.91 M in cash with (39.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Iterum Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Iterum Therapeutics Regains Full Nasdaq Compliance |
Iterum Therapeutics Returns Distribution Density
The distribution of Iterum Therapeutics' historical returns is an attempt to chart the uncertainty of Iterum Therapeutics' future price movements. The chart of the probability distribution of Iterum Therapeutics daily returns describes the distribution of returns around its average expected value. We use Iterum Therapeutics PLC price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Iterum Therapeutics returns is essential to provide solid investment advice for Iterum Therapeutics.
| Mean Return | 0.99 | Value At Risk | -6.19 | Potential Upside | 8.59 | Standard Deviation | 9.49 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Iterum Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Iterum Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Iterum Therapeutics, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Iterum Therapeutics PLC back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | Planning Capital Management Corp | 2024-09-30 | 40.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 12.0 | Hm Payson & Co | 2024-09-30 | 3.0 | Ubs Group Ag | 2024-06-30 | 1.0 | Ancora Advisors Llc | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 | Kelly Financial Services Llc | 2024-09-30 | 0.0 | Millennium Management Llc | 2024-06-30 | 0.0 | Renaissance Technologies Corp | 2024-09-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 1.3 M | New Leaf Venture Partners, L.l.c. | 2024-09-30 | 345 K |
Iterum Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | 40.1M | (11K) | (54.5M) | 14.0M | 14.2M | 14.9M | |
| Change In Cash | (39.8M) | 9.9M | 12.7M | (6.4M) | (15.0M) | (14.3M) | |
| Net Borrowings | (1.0M) | (5.5M) | (6.5M) | (2.3M) | (2.0M) | (1.9M) | |
| Free Cash Flow | (78.9M) | (54.5M) | (15.9M) | (18.5M) | (39.3M) | (41.3M) | |
| Depreciation | 152K | 161K | 2.1M | 1.8M | 1.8M | 1.8M | |
| Capital Expenditures | 24K | 11K | 61K | 62K | 13K | 12.4K | |
| Net Income | (103.1M) | (52.0M) | (91.6M) | (44.4M) | (38.4M) | (40.3M) | |
| End Period Cash Flow | 4.9M | 14.8M | 27.5M | 21.1M | 6.1M | 5.8M | |
| Change To Netincome | 5.8M | 8.1M | 70.0M | 19.5M | 22.4M | 16.8M | |
| Other Non Cash Items | 4.1M | 17.7M | 8.1M | 17.1M | (6.3M) | (5.9M) |
Iterum Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Iterum Therapeutics or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Iterum Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Iterum stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 1.17 | |
β | Beta against Dow Jones | -1.57 | |
σ | Overall volatility | 9.60 | |
Ir | Information ratio | 0.09 |
Iterum Therapeutics Volatility Alert
Iterum Therapeutics PLC is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Iterum Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Iterum Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Iterum Therapeutics Fundamentals Vs Peers
Comparing Iterum Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Iterum Therapeutics' direct or indirect competition across all of the common fundamentals between Iterum Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Iterum Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Iterum Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Iterum Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Iterum Therapeutics to competition |
| Fundamentals | Iterum Therapeutics | Peer Average |
| Return On Equity | -5.56 | -0.31 |
| Return On Asset | -0.73 | -0.14 |
| Current Valuation | 57.74 M | 16.62 B |
| Shares Outstanding | 27.52 M | 571.82 M |
| Shares Owned By Insiders | 1.81 % | 10.09 % |
| Shares Owned By Institutions | 8.98 % | 39.21 % |
| Number Of Shares Shorted | 2.53 M | 4.71 M |
| Price To Earning | 16.21 X | 28.72 X |
| Price To Book | 6.03 X | 9.51 X |
| Price To Sales | 1,350 X | 11.42 X |
| Gross Profit | 37 K | 27.38 B |
| EBITDA | (34.58 M) | 3.9 B |
| Net Income | (38.37 M) | 570.98 M |
| Cash And Equivalents | 68.91 M | 2.7 B |
| Cash Per Share | 5.63 X | 5.01 X |
| Total Debt | 18.96 M | 5.32 B |
| Debt To Equity | 0.58 % | 48.70 % |
| Current Ratio | 9.47 X | 2.16 X |
| Book Value Per Share | (0.47) X | 1.93 K |
| Cash Flow From Operations | (39.33 M) | 971.22 M |
| Short Ratio | 0.46 X | 4.00 X |
| Earnings Per Share | (1.76) X | 3.12 X |
| Target Price | 7.5 | |
| Number Of Employees | 14 | 18.84 K |
| Beta | 2.25 | -0.15 |
| Market Capitalization | 49.8 M | 19.03 B |
| Total Asset | 26.26 M | 29.47 B |
| Retained Earnings | (461.3 M) | 9.33 B |
| Working Capital | 12.08 M | 1.48 B |
| Current Asset | 36.86 M | 9.34 B |
| Current Liabilities | 5.97 M | 7.9 B |
| Net Asset | 26.26 M |
Note: Acquisition by Ahrens Brenton Karl of 113276 shares of Iterum Therapeutics at 0.2 subject to Rule 16b-3 [view details]
Iterum Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Iterum . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Iterum Therapeutics Buy or Sell Advice
When is the right time to buy or sell Iterum Therapeutics PLC? Buying financial instruments such as Iterum Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Iterum Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Funds Thematic Idea Now
Consumer Funds
Funds or Etfs that invest in consumer products such as packaged goods, clothing, food, beverages and retail services. The Consumer Funds theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Iterum Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.76) | Quarterly Revenue Growth (1.00) | Return On Assets (0.73) | Return On Equity (5.56) |
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.